Amphastar Pharmaceuticals Inc. (AMPH)
NASDAQ: AMPHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AMPH stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.20B
- P/E (TTM)
- 12.96
- Forward P/E
- 8.43
- EPS (TTM)
- $2.18
- Dividend yield
- None
- 52-week range
- 16.65 – 31.00
- Day range
- 27.79 – 28.70
- Volume / Avg
- 497.44K / 475.35K
- Beta
- —
- Shares outstanding
- 42.65M
52-week range
AMPH stock today
On Nov 20, AMPH ended the session at $28.25, adding $0.14 (0.50%), versus the S&P 500's 3.70% decline. At this level, AMPH sits near the top of its 52-week range of $16.65 to $31.00: 8.9% below the high, set on Nov 6, 2026 and 69.7% above the low. AMPH is up 5.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 8.6%.
Amphastar Pharmaceuticals trades at 13.0x its trailing twelve-month earnings per share of $2.18. Its forward P/E of 8.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Amphastar Pharmaceuticals
Company profileAmphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Yongfeng Zhang Ph.D.
- Headquarters
- Rancho Cucamonga, CA
- Employees
- 1,976
- IPO year
- 2014
- Website
- amphastar.com
Financial highlights
Full financialsIn fiscal 2025, Amphastar Pharmaceuticals generated $719.9 million in revenue, down 1.7% from fiscal 2024, its first annual decline since 2017. Net income was $98.1 million (-38.5% year over year), for a net margin of 13.6% versus a median of 18.3% in the prior 5 years. Gross margin was 49.5% (down from 51.1%) and operating margin 19.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $719.89M | $731.97M | $644.39M | $498.99M | $437.77M |
| Growth | -1.65% | +13.59% | +29.14% | +13.98% | +25.13% |
| Net income | $98.09M | $159.52M | $137.54M | $91.39M | $62.12M |
| EPS (diluted) | $2.03 | $3.06 | $2.60 | $1.74 | $1.25 |
Analyst forecast
ForecastConsensus (7 analysts)
hold
Avg. price target
$24.50-13.27%
- Strong buy 0
- Buy 0
- Hold 6
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $0.87 vs $0.80
- Surprise
- +8.75%
AMPH news
All AMPH news- Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in LondonPR Newswire
- Amphastar Pharmaceuticals Consensus Price Target Increased 12.34% to $25.78Nasdaq
- Amphastar (AMPH) Q3 2026 Earnings Call TranscriptNasdaqAMPH, ET
- Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026PR Newswire
- BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue EstimatesNasdaqBBIO, AMPH
- Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026PR Newswire
- Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and ViatrisNasdaqAMPH, VTRS
- 3 Generic Drug Stocks to Watch Amid Improving Industry TrendsNasdaqAMPH, VTRS
Amphastar Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GHRSGH Research PLC | 17.53 | -5.55% | $1.20B | vs AMPH |
| MLYSMineralys Therapeutics Inc. | 13.66 | -3.53% | $1.21B | vs AMPH |
| OCULOcular Therapeutix Inc. | 5.57 | -4.95% | $1.23B | vs AMPH |
| GENBGenerate Biomedicines Inc. | 9.54 | -8.00% | $1.23B | vs AMPH |
| OPKOPKO Health Inc. | 1.57 | -2.48% | $1.17B | vs AMPH |
| SLNSilence Therapeutics Plc American Depository Share | 19.81 | 0.00% | $1.23B | vs AMPH |
| MNKDMannKind Corporation | 3.85 | -2.53% | $1.24B | vs AMPH |
| GPCRStructure Therapeutics Inc. ADR | 16.13 | -5.78% | $1.15B | vs AMPH |
Indexes, lists and sector
Amphastar Pharmaceuticals stock FAQ
What is Amphastar Pharmaceuticals's stock price today?
AMPH last traded at $28.25 as of Nov 20, 4:00 PM EST, up 0.50% on the day. Prices are delayed at least 15 minutes.
What is AMPH's P/E ratio?
AMPH trades at a trailing P/E ratio of 12.96 and a forward P/E of 8.43.
Who is Amphastar Pharmaceuticals's CEO?
Dr. Yongfeng Zhang Ph.D. is the chief executive officer of Amphastar Pharmaceuticals Inc., which has about 1,976 employees.
What is the AMPH 52-week high?
The 52-week high for AMPH is $31.00 and the 52-week low is $16.65. The stock is currently 8.9% below its high.